摘要
目的:探讨哌罗匹隆治疗精神分裂症的疗效及对内分泌的影响。方法:64例精神分裂症患者分为哌罗匹隆组和利培酮组各32例,分别予哌罗匹隆和利培酮治疗6周。采用阳性和阴性症状量表(PANSS)及治疗中出现的症状量表(TESS)在治疗前后评定疗效及不良反应,同时测定血清催乳素(PRL)及促甲状腺激素(TSH)、三碘甲状腺原氨酸(T3)、游离三碘甲状腺原氨酸(FT3)、甲状腺素(T4)、游离甲状腺素(FT4)水平。结果:哌罗匹隆组总有效率78.13%,利培酮组81.25%(χ2=0.097,P>0.05)。两组治疗后PANSS评分均较治疗前显著下降(P<0.05或P<0.01);两组TESS评分治疗1周和6周差异均无统计学意义(t=-1.84,-1.35;P均>0.05)。哌罗匹隆组PRL(t=-1.26)及各项甲状腺激素(t=0.97～1.88)水平治疗前后差异无统计学意义(P均>0.05)。结论:哌罗匹隆治疗精神分裂症疗效与利培酮相当,但对PRL和甲状腺激素的影响较小。
Objective：To explore the efficacy and safety of perospirone of the treatment of schizophrenia and its impact on the endocrine in the treatment of patients with schizophrenia. Method：64 patients with schizophrenia were randomly divided into two groups,perospirone group（ n = 32） and risperidone group （ n = 32） for six weeks. Efficacy and adverse reactions were assessed using the positive and negative symptoms scale （ PANSS） and treatment emergent symptoms scale （ TESS） before and after the treatment. And serum prolactin （ PRL） and TSH、T3 ,FT3 ,T4 ,FT4 were tested. Results：Total effective rate of perospirone group was 78. 13% and risperidone group 81. 25% （ χ2 = 0. 097,P 0. 05） . PANSS scores of the two groups in the each stage were significantly decreased （ P 0. 05 or P 0. 01） after treatment; TESS total score of the two groups after treatment was no significant difference （ t = - 1. 84,- 1. 35; P 0. 05） . Serum PRL （ t = - 1. 26） and TSH,T3 , FT3 ,T4 ,FT4 （ t =0. 97 ～1. 88） of perospirone group showed no significant difference between before and after the treatment （ all P 0. 05） . Conclusion：The efficacy of perospirone is similar to risperidone in treatment of schizophrenia and has less impact on serum PRL and thyroid function.
出处
《临床精神医学杂志》
2013年第3期194-195,共2页
Journal of Clinical Psychiatry
